Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 662125Generated: November 1, 2026

Triethylamine → 1,1-dimethylethyl 4-[(3'-{[({5-[({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)carbonyl]-3-pyridinyl}carbonyl)amino]methyl}-3-biphenylyl)methyl]-1-piperidinecarboxylate

https://huagongshe.com/reaction/662125

Reaction equation

Participants

RoleNameHCIDCharge
ReactantTriethylamineHCID 8471—
ReactantMethanaminium, N-((1H-benzotriazol-1-yloxy)(dimethylamino)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 2733084—
Reactanttert-Butyl 4-{[3'-(aminomethyl)biphenyl-3-yl]methyl}piperidine-1-carboxylateHCID 57813360—
Reactant5-[({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)carbonyl]-3-pyridinecarboxylic acidHCID 57819387—
SolventDichloromethaneHCID 6344—
Product1,1-dimethylethyl 4-[(3'-{[({5-[({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)carbonyl]-3-pyridinyl}carbonyl)amino]methyl}-3-biphenylyl)methyl]-1-piperidinecarboxylateHCID 68913009—

Reaction Steps

A mixture of 5-[({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)carbonyl]-3-pyridinecarboxylic acid (50 mg, 0.110 mmol), 1,1-dimethylethyl 4-{[3′-(aminomethyl)-3-biphenylyl]methyl}-1-piperidinecarboxylate (42.0 mg, 0.110 mmol), HBTU (o-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate) (50.3 mg, 0.133 mmol) and Et3N (0.046 ml, 0.331 mmol) in DCM was stirred at room temperature over the weekend. The reaction was quenched with saturated NaHCO3, and extracted with DCM twice. The combined organic layers were washed with brine and then concentrated under vacuum to give a crude residue. It was then purified with a Gilson HPLC (with 0.1% TFA in the solvents), eluting with 10 to 70% CH3CN in water at a flow rate of 20 mL/min. The product fractions were dried using a GeneVac and then combined to give 1,1-dimethylethyl 4-[(3′-{[({5-[({[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}amino)carbonyl]-3-pyridinyl}carbonyl)amino]methyl}-3-biphenylyl)methyl]-1-piperidinecarboxylate. It was then dissolved in 2 mL of 25% TFA in DCM and stirred at room temperature for 3 h. The crude product was purified with a Gilson HPLC (with 0.1% TFA in the solvents), eluting with 10 to 70% CH3CN in water at a flow rate of 20 mL/min. The product fractions were combined and converted to the free base with 1 N NaOH, and the basified solution was extracted with ethyl acetate twice. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum to N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-N′-{[3′-(4-piperidinylmethyl)-3-biphenylyl]methyl}-3,5-pyridinedicarboxamide as a solid (3.5 mg, 4.4%). LC-MS m/z 715 (M+H)+, 0.77 min (ret time).

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS08084449B2
Source datasetuspto-grants-2011_12
ORD IDord-84418858e748458e95c8586cb34fff00
Source noteuspto-grants-2011_12